HC Wainwright Lifts Earnings Estimates for GH Research

GH Research PLC (NASDAQ:GHRS – Free Report) – HC Wainwright upped their FY2026 earnings per share (EPS) estimates for shares of GH Research in a report issued on Tuesday, November 17th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings of ($1.00) per share for the year, up from their prior estimate of ($1.14). HC Wainwright currently has a “Buy” rating and a $55.00 price objective on the stock. The consensus estimate for GH Research’s current full-year earnings is ($1.08) per share. HC Wainwright also issued estimates for GH Research’s Q4 2026 earnings at ($0.29) EPS, Q1 2027 earnings at ($0.32) EPS, Q2 2027 earnings at ($0.37) EPS, Q4 2027 earnings at ($0.47) EPS, FY2027 earnings at ($1.59) EPS, FY2028 earnings at ($1.70) EPS, FY2029 earnings at ($1.90) EPS and FY2030 earnings at ($0.40) EPS.

GH Research (NASDAQ:GHRS – Get Free Report) last issued its quarterly earnings results on Friday, November 13th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.13.

A number of other research firms also recently weighed in on GHRS. Cantor Fitzgerald increased their target price on shares of GH Research from $35.00 to $40.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Stifel Nicolaus set a $38.00 price target on shares of GH Research in a research report on Friday, November 13th. Guggenheim boosted their price target on shares of GH Research from $40.00 to $46.00 and gave the stock a “buy” rating in a research report on Wednesday. Needham & Company LLC upped their price objective on shares of GH Research from $32.00 to $39.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Finally, Wells Fargo & Company started coverage on shares of GH Research in a research report on Monday, July 27th. They set an “overweight” rating and a $44.00 price objective for the company. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $44.00.

View Our Latest Analysis on GH Research

GH Research Price Performance

GH Research stock opened at $17.53 on Thursday. The stock’s 50 day moving average is $21.37 and its 200 day moving average is $21.70. GH Research has a one year low of $12.04 and a one year high of $31.44. The firm has a market cap of $1.20 billion, a P/E ratio of -18.45 and a beta of 1.31.

Institutional Investors Weigh In On GH Research

A number of hedge funds have recently added to or reduced their stakes in the business. Militia Capital Management LLC acquired a new position in GH Research in the third quarter valued at approximately $470,000. Bellevue Group AG bought a new position in shares of GH Research during the 3rd quarter worth approximately $109,000. Marshall Wace LLP grew its position in shares of GH Research by 46.3% during the 3rd quarter. Marshall Wace LLP now owns 68,298 shares of the company’s stock worth $1,604,000 after buying an additional 21,601 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of GH Research during the 3rd quarter worth approximately $82,000. Finally, China Universal Asset Management Co. Ltd. grew its position in shares of GH Research by 30.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 17,525 shares of the company’s stock worth $432,000 after buying an additional 4,106 shares during the period. 56.90% of the stock is currently owned by institutional investors.

Key GH Research News

Investors following GHRS have been watching these news items:

  • Positive Sentiment: Wall Street analysts’ average price target implies about 128.7% potential upside, and the article also points to a positive trend in earnings estimate revisions. Price targets are opinions, not guarantees. Read article
  • Positive Sentiment: Guggenheim analyst commentary also indicates an expectation that GHRS shares could rise. Read article
  • Negative Sentiment: A separate report attributed a sharp share decline to an analyst downgrade, a potential near-term headwind that contrasts with the bullish targets from other analysts. The entry does not specify the downgrading analyst or rationale. Read article

GH Research Company Profile

(Get Free Report)

GH Research plc is a clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and neurological disorders. The company is based in Dublin, Ireland, and its research centers on mebufotenin, also known as 5-MeO-DMT. Its lead investigational candidate, GH001, is an inhaled formulation being studied for treatment-resistant depression. GH Research is also developing other mebufotenin-based candidates and delivery approaches. These treatments remain investigational and are not approved for general use.

Read More

Earnings History and Estimates for GH Research (NASDAQ:GHRS)

Receive News & Ratings for GH Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GH Research and related companies with MarketBeat.com's FREE daily email newsletter.